Ionis Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- AMD shares fall amid AI chip sector selloff
- Alphabet shares drop ahead of earnings next week
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 14c, Revenues Miss
November 6, 2018 7:17 AM ESTIonis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.03), $0.14 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $145 million versus the consensus estimate of $152.68 million.
"We enter the fourth quarter in a position of financial strength, driven by strong worldwide SPINRAZA sales. In addition, we achieved numerous successes during the quarter... More



